β-glucosidase

β-Glucosidase is a glucoside bond hydrolase widely found in organisms and is involved in glucose metabolism, which can be used to study diseases caused by abnormal glucose metabolism.

α-Glucosidase-IN-4 is a potent α-glucosidase inhibitor exhibiting antihypertensive and hypoglycemic activity.

α-Amylase/α-Glucosidase-IN-1 (compound 33) is an effective inhibitor of α-amylase and α-glucosidase, with IC50 values of 2.01 and 2.09 μM, respectively. Kinetic studies predict that α-Amylase/α-Glucosidase-IN-1 has potential anti-hyperglycemia properties [1].

α-Glucosidase-IN-8 (Compound 4k) is a potent competitive inhibitor of α-glucosidase with an impressive IC50 value of 0.18 μg/mL [1].

α-Glucosidase-IN-9 (compound 7) is a highly potent α-glucosidase inhibitor with an IC50 of 55.6 μM, suitable for type II diabetes research [1].

α-Glucosidase-IN-16 is a highly effective and orally bioavailable inhibitor of α-glucosidase, displaying a remarkable IC50 value of 3.28 μM. This compound significantly decreases blood glucose levels in Streptozotocin-induced diabetic rats and exhibits noteworthy antidiabetic activity [1].

α-Glucosidase-IN-2 (compound 5d) is a potent α-glucosidase inhibitor with an inhibitory concentration (IC50) of 9.48 μM, functioning as an antidiabetic agent [1].

α-Glucosidase-IN-20 (Compound 3B) is a highly effective, orally active α-glucosidase inhibitor with potent anti-diabetic properties, evidenced by an IC50 value of 3.01 μM [1].

α-Glucosidase-IN-15 (Compound 14B) exhibits potent α-glucosidase inhibitory activity with an IC50 value of 3.34 μM and possesses antidiabetic properties [1].

α-Glucosidase-IN-18 (7B) is an orally active α-glucosidase inhibitor with an IC50 value of 3.96 μM, exhibiting antidiabetic properties [1].

α-Amylase/α-Glucosidase-IN-2 (compound 5) exhibits strong inhibition of α-amylase and α-glucosidase enzymes, with IC50 values of 13.02 μM and 13.09 μM, respectively, showing promise for investigating diabetic complications [1].

α-Glucosidase-IN-21 (Compound 2B) is a highly potent, orally bioavailable α-glucosidase inhibitor with an IC50 value of 2.62 μM, demonstrating remarkable anti-diabetic properties [1].

α-Glucosidase-IN-11 is a highly permeable competitive inhibitor of α-glucosidase (IC50: 0.56 μM) that binds to the Trp residue in α-glucosidase, affecting protein folding and regulating blood glucose levels. [Topoisomerase II]

Alpha-Glucosidase-IN-19 (Compound 6B) is an orally active alpha-glucosidase inhibitor (IC50: 3.63 μM) with antidiabetic effects.

α-Glucosidase-IN-17 (Compound 12B) is a potent, orally active α-glucosidase inhibitor with antidiabetic activity, demonstrating an inhibitory concentration (IC50) of 3.79 μM [1].

α-Glucosidase-IN-10 (compound 13) is a potent α-glucosidase inhibitor with an IC50 of 92.7 μM, useful for studying type II diabetes.

α-Glucosidase-IN-6 is a competitive inhibitor of α-glucosidase (IC50: 5.69 μM) and exhibits potential for anti-diabetic studies.

α-Glucosidase-IN-13 is an inhibitor of α-glucosidase (IC50: 5.69 μM).

α-Glucosidase-IN-14 is a potent inhibitor of α-glucosidase (IC50: 5.22 μM).

α-Glucosidase-IN-12 is a potent inhibitor of α-glucosidase (IC50: 10.20 μM).

α-Glucosidase-IN-3, an oleanolic acid oxime ester derivative, targets α-glucosidase and α-amylase with an IC50 value of 0.35 μM for α-glucosidase.

α-Glucosidase-IN-24 (Compound 13), an α-Glucosidase inhibitor derived from Swertia kouitchensis [1], exhibits an IC50 value of 451 μM.

α-Glucosidase-IN-26 (Compound 7i), with an IC50 value of 4.63 µM, functions as an α-glucosidase inhibitor and is utilized in type 2 diabetes mellitus (T2DM) research [1].

α-Glucosidase-IN-28 (Compound 18) is an α-glucosidase inhibitor with an IC50 of 0.62 μM and Ki of 3.93 μM, interacting with the enzyme's original binding site (OBS) and forming multiple hydrophobic interactions with adjacent amino acids. This compound is used in diabetes and related diseases research [1].